Trevi Therapeutics (TRVI) Cash from Operations (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Cash from Operations of 16689000.0 for Q1 2026, down 23.83% year-over-year from 21911120.6 in Q1 2025, and down 118.7% quarter-over-quarter from 7631000.0 in Q4 2025.
Trevi Therapeutics (TRVI) Cash from Operations (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Cash from Operations history runs 9 years deep, the most recent figure standing at 16689000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 23.83% year-over-year to 16689000.0; the TTM figure through Mar 2026 stood at 45301000.0 (down 9.78% YoY), while the FY2025 annual figure was 42089000.0, down 10.02% from the prior year.
- Cash from Operations for Q1 2026 stood at 16689000.0, down from 7631000.0 in the prior quarter.
- The five-year high for Cash from Operations was 6176000.0 in Q2 2022, with the low at 16689000.0 in Q1 2026.
- The 5-year median for Cash from Operations is 8683000.0 (2024), against an average of 9230529.41.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations rose 21.8% in 2022, then slumped 59.89% in 2023.
- Trevi Therapeutics' Cash from Operations stood at 6331000.0 in 2022, then slipped by 0.44% to 6359000.0 in 2023, then tumbled by 50.18% to 9550000.0 in 2024, then increased by 20.09% to 7631000.0 in 2025, then slumped by 118.7% to 16689000.0 in 2026.
- Business Quant data shows TRVI's Cash from Operations at 16689000.0 in Q1 2026, 7631000.0 in Q4 2025, and 10880000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | -17.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.43 Mn |
| Jun 30, 2026 | -17.43 Mn |
| Mar 31, 2026 | -16.69 Mn |
| Mar 31, 2026 | -16.69 Mn |
| Dec 31, 2025 | -7.63 Mn |
| Dec 31, 2025 | -7.63 Mn |
| Sep 30, 2025 | -10.88 Mn |
| Sep 30, 2025 | -10.88 Mn |
| Jun 30, 2025 | -10.10 Mn |
| Jun 30, 2025 | -10.10 Mn |
| Mar 31, 2025 | -13.48 Mn |
| Mar 31, 2025 | -13.48 Mn |
| Dec 31, 2024 | -9.55 Mn |
| Dec 31, 2024 | -9.55 Mn |
| Sep 30, 2024 | -9.56 Mn |
| Sep 30, 2024 | -9.56 Mn |
| Jun 30, 2024 | -8.68 Mn |
| Jun 30, 2024 | -8.68 Mn |
| Mar 31, 2024 | -10.47 Mn |
| Mar 31, 2024 | -10.47 Mn |